These findings indicate that BA, a potential EGFR inhibitor, strengthens the ability of gefitinib and osimertinib to inhibit the proliferation of NSCLC cells and enhances EGFR-mediated autophagy in intrinsically resistant lung cancer cell lines. The gene discussed is EGFR; the disease is lung cancer.